Showing results (471-480 of 502) with videos related to

Sort By:
Pageof 51
Cancer Discovery|April 23, 2016
EGFR Fusions as Novel Therapeutic Targets in Lung CancerKartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, et al.
Investigational New Drugs|February 7, 2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trialsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2015
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung CancerTaofeek K Owonikoko, Suresh S Ramalingam, Daniel L Miller, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancerCharles M Rudin, Christine L Hann, Edward B Garon, et al.
The Lancet. Oncology|November 14, 2017
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trialHeather A Wakelee, Suzanne E Dahlberg, Steven M Keller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Pageof 51